Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease

Yazar, Tamer; Yazar, Hülya Olgun; Zayimoğlu, Emel; Çankaya, Soner

doi:10.1007/s10072-018-3439-6

Cited by 38 publications

(46 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevalence for sarcopenia in our cohort of PS patients was 13.5% (Table 1), i.e., >2-fold higher than in the normal German population. Studies investigating sarcopenia in iPD patients have found different prevalence rates, ranging from 6.6 to 25.9% (for a better comparison, mean values were calculated only for those studies that reported prevalence rates separated for gender) [10-13]. These variations in prevalence are based on different cut-off values for muscle mass, gait speed, and hand-grip strength as well as different methods for measuring muscle mass (BIA vs. dual-energy X-ray absorptiometry [DXA]).…”

Section: Discussionmentioning

confidence: 99%

“…These authors used DXA for muscle mass measurement and it was an Asian cohort, so a comparison of absolute values should be avoided. In another study investigating the prevalence of sarcopenia in iPD patients, a lower SMI was found in the iPD group, although the difference did not reach significance [13]. The following 2 reasons may contribute to a higher muscle mass in iPD patients: continuous levodopa medication possibly leads to an increased release of growth hormones that have a strong anabolic effect on muscle [19, 20], and symptoms such as bradykinesia, rigidity, and tremor can “train” muscles comparably to sports activities [10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes

et al. 2020

View full text Add to dashboard Cite

Introduction: Pathogenesis in a subgroup of sarcopenic patients seems to be based on a reduced number of motor neurons. This study aimed at investigating the overlap between sarcopenia and neurodegeneration, as reflected by a low number of motor neurons in patients with Parkinsonian syndromes (PS). Methods: The motor unit number index (MU-NIX) of the hypothenar muscle was used to assess the number and size (MUSIX) of motor units (MUs) in patients with idiopathic Parkinson disease (iPD, n = 53), patients with atypical Parkinsonian syndrome (aPS, n = 21), and a control group (n = 30). Mean age of participants was 70.3 years and 54.1% were female. Skeletal muscle mass by bioelectrical impedance analysis, hand-grip strength and gait speed were measured. Based on these assessments, sarcopenia was diagnosed according to the criteria of the European Working Group on Sarcopenia in Older People. Results: Sarcopenia criteria were met by 10 patients with PS (13.5%). The study group had significantly lower MUNIX values than the control group (109 [SD ±39.1] vs. 129 [SD ±45.1]; p = 0.020) even after adjustment for age and sex. Three of the 5 sarcopenic iPD patients (75%) had pathological low MUNIX values (< 80). Discussion/Conclusion: Sarcopenia is a frequent comorbidity in PS. The pathologically low MUNIX values found in 75% of our sarcopenic iPD patients provides further support for the existence of a neurodegenerative overlap syndrome with a reduced number of MUs potentially leading to sarcopenia. This finding warrants further evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…PD patients are likely to experience nausea, dyspepsia, constipation, medication side effects, dysphagia, anorexia and depressive symptoms that cause reduced energy intake [14]. Thirdly, it has also been found that PD patients have lower levels of physical activity (in terms of amount and intensity) compared to healthy older adults [15–17].…”

Section: Discussionmentioning

confidence: 99%

“…The risk of falls is greater in this population compared to healthy individuals and those with other neurological diseases with high risk of falls such polyneuropathy, spinal disorders and multiple sclerosis [5]. It is very important to early detect sarcopenia and fall risk in PD patients because they can benefit from simple interventions such as high-protein diet and resistance exercise training [6].…”

Section: Introductionmentioning

confidence: 99%

Clinical correlates of sarcopenia and falls in Parkinson’s disease

Lima

Almeida

Bonfadini

et al. 2019

Preprint

View full text Add to dashboard Cite

35 Background: Sarcopenia is a complex and multifactorial geriatric condition seen in 36 several chronic degenerative diseases. This study aimed to screen for sarcopenia and fall 37 risk in a sample of Parkinson's disease (PD) patients and to investigate demographic 38 and clinical factors associated.39 Methods: This is a cross-sectional study. We evaluated 218 PD patients at the 40 Movement Disorders Clinic in Fortaleza, Brazil, and collected clinical data including 41 experiencing falls in the six months prior to their medical visit. Probable sarcopenia 42 diagnosis was confirmed by using a sarcopenia screening tool (SARC-F questionnaire) 43 and the presence of low muscle strength.44 Results: One hundred and twenty-one patients (55.5%) were screened positive for 45 sarcopenia using the SARC-F and 103 (47.4%) met the criteria for probable sarcopenia.46 Disease duration, modified Hoehn and Yahr stage, Schwab and England Activities of 47 Daily Living Scale score, levodopa equivalent dose, probable sarcopenia and positive 48 SARC-F screening were all associated with experiencing falls in the prior six months.49 Disease duration, lower quality of life and female gender were independently associated 50 with sarcopenia. Experiencing falls in the prior six months was significantly more 51 frequent among patients screened positive in the SARC-F compared to those screened 52 negative. 53 Conclusions: Sarcopenia and PD share common pathways and may affect each other's 54 prognosis and patients' quality of life. Since sarcopenia is associated with lower quality 55 of life and increased risk of falls, active case finding, diagnosis and proper management 56 of sarcopenia in PD patients is essential. 57 58 Key words: Parkinson's disease; Sarcopenia; Falls 3 59 60 INTRODUCTION 61Sarcopenia is a complex and multifactorial geriatric condition seen in several 62 chronic degenerative diseases. It stems from abnormally reduced muscle mass quality 63 and quantity and is associated to several negative outcomes such as falls, disability, 64 poor quality of life, institutionalization, hospitalization, and death [1]. The prevalence of 65 sarcopenia has increased and it has become a serious global public health concern [2].66 Patients with Parkinson's disease (PD) show higher prevalence of sarcopenia and higher 67 frequency of falls compared to non-PD patients [3,4]. Despite its importance, few 68 studies have assessed the prevalence and characteristics of sarcopenia in this population. 69Falls are a serious concern in PD with an annual incidence of 60% among PD 70 patients. The risk of falls is greater in this population compared to healthy individuals 71 and those with other neurological diseases with high risk of falls such polyneuropathy, 72 spinal disorders and multiple sclerosis [5]. It is very important to early detect sarcopenia 73 and fall risk in PD patients because they can benefit from simple interventions such as 74 high-protein diet and resistance exercise training [6]. 75 To the best of our knowledge, there are no large st...

show abstract

“…We have read the article by Yazar et al [1] with interest. In this article, authors aimed to identify the incidence of sarcopenia and dynapenia according to disease stage among idiopathic Parkinson's disease patients.…”

Section: Dear Editormentioning

confidence: 99%